<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15511">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02904954</url>
  </required_header>
  <id_info>
    <org_study_id>1501015795</org_study_id>
    <nct_id>NCT02904954</nct_id>
  </id_info>
  <brief_title>Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer</brief_title>
  <official_title>A Randomized Phase 2 Trial of Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out the effectiveness of the drug durvalumab (MEDI4736)
      with or without stereotactic body radiation therapy (SBRT) as treatment for stage IB and II
      non-small cell lung cancer (NSCLC) prior to surgery and one year following surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized open label phase II trial of preoperative anti-PD-L1 antibody
      durvalumab with or without concurrent non-ablative radiation followed by surgical resection
      and postoperative monthly maintenance durvalumab for twelve months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Confirmed disease recurrence or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective clinical response rate</measure>
    <time_frame>Up to 2-3 weeks post neoadjuvant treatment followed by surgery</time_frame>
    <description>Disease response to pre-operative treatment measured according to RECIST criteria 1.1</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v. 4.0</measure>
    <time_frame>Up to 72 weeks</time_frame>
    <description>Toxicities assessed and graded according to CTCAE v. 4.0</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Arm 1 (Durvalumab monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab (MEDI4736) via IV infusion administered pre-operatively every 3 weeks for 2 cycles followed by surgical resection. Durvalumab monotherapy will be given for 12 months post-operatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (Durvalumab plus SBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab (MEDI4736) via IV infusion administered pre-operatively every 3 weeks for 2 cycles plus radiotherapy delivered in 3 daily fractions starting concurrently with the first cycle of durvalumab (MEDI4736) followed by surgical resection. Durvalumab monotherapy will be given for 12 months post-operatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Intravenously</description>
    <arm_group_label>Arm 1 (Durvalumab monotherapy)</arm_group_label>
    <arm_group_label>Arm 2 (Durvalumab plus SBRT)</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Durvalumab plus SBRT</intervention_name>
    <description>Intravenously</description>
    <arm_group_label>Arm 2 (Durvalumab plus SBRT)</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has histologically or cytologically proven clinical stages IB /II NSCLC and
             is considered eligible for surgical resection with curative intent.

          2. Tumor amenable to pre-treatment core needle biopsy without unacceptable risk of a
             major procedural complication.

          3. Measureable disease, as defined by RECIST v1.1.

          4. Written informed consent and HIPAA obtained from the subject prior to performing any
             protocol-related procedures.

          5. Age &gt; 18 years at time of study entry

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          7. Adequate normal organ and marrow function as defined below:

               -  Haemoglobin ≥ 9.0 g/dL

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (&gt; 1500 per mm3)

               -  Platelet count ≥ 100 x 109/L (&gt;100,000 per mm3)

               -  Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN). This will not
                  apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent
                  hyperbilirubinemia that is predominantly unconjugated in the absence of
                  hemolysis or hepatic pathology), who will be allowed only in consultation with
                  their physician.

               -  AST (SGOT)/ALT (SGPT), and alkaline phosphatase ≤ 2.5 x institutional upper
                  limit of normal (ULN).

               -  Serum creatinine CL&gt;40 mL/min by the Cockcroft-Gault formula (Cockcroft and
                  Gault 1976) or by 24-hour urine collection for determination of creatinine
                  clearance:

             Males:

             Creatinine CL (mL/min)=Weight (kg) x (140 - Age) / 72 x serum creatinine (mg/dL)

             Females:

             Creatinine CL (mL/min)=Weight (kg) x (140 - Age) x 0.85 / 72 x serum creatinine
             (mg/dL)

          8. Female subjects must either be of non-reproductive potential (i.e., post-menopausal
             by history: ≥60 years old and no menses for ≥1 year without an alternative medical
             cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history
             of bilateral oophorectomy) or must have a negative serum pregnancy test upon study
             entry.

          9. Subject is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including follow
             up.

         10. No prior therapy for their lung cancer. -

        Exclusion Criteria:

          1. Participation in another clinical study with an investigational product during the
             last 3 weeks.

          2. Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab.

          3. History of another primary malignancy except for:

               -  Malignancy treated with curative intent and with no known active disease ≥3
                  years before the first dose of study drug and of low potential risk for
                  recurrence.

               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease.

               -  Adequately treated carcinoma in situ without evidence of disease eg, cervical
                  cancer in situ, in-situ urinary bladder cancer , treated localized prostate
                  cancer and ductal carcinoma-in situ.

          4. Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3
             electrocardiograms (ECGs) using Frediricia's Correction

          5. Current or prior use of immunosuppressive medication within 28 days before the first
             dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of
             prednisone, or an equivalent corticosteroid.

          6. Any unresolved toxicity (CTCAE grade 2) from previous anti-cancer therapy. Subjects
             with irreversible toxicity that is not reasonably expected to be exacerbated by the
             investigational product may be included (e.g., hearing loss, peripherally
             neuropathy).

          7. Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous
             immunotherapy agent, or any unresolved irAE &gt;Grade 1.

          8. Active or prior documented autoimmune disease within the past 2 years NOTE: Subjects
             with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within
             the past 2 years) are not excluded. Patients with a history of autoimmune
             hypothyroidism on a stable dose of thyroid replacement hormone are eligible.

          9. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease,
             ulcerative colitis).

         10. History of primary immunodeficiency.

         11. History of allogeneic organ transplant.

         12. History of hypersensitivity to durvalumab or any excipient.

         13. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active
             bleeding diatheses including any subject known to have evidence of acute or chronic
             hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric
             illness/social situations that would limit compliance with study requirements or
             compromise the ability of the subject to give written informed consent.

         14. Known history of previous clinical diagnosis of tuberculosis.

         15. History of leptomeningeal carcinomatosis.

         16. Receipt of live attenuated vaccination within 30 days prior to study entry or within
             30 days of receiving durvalumab.

         17. Female subjects who are pregnant, breast-feeding or male or female patients of
             reproductive potential who are not employing an effective method of birth control.

         18. Any condition that, in the opinion of the investigator, would interfere with
             evaluation of study treatment or interpretation of patient safety or study results

         19. Subjects with uncontrolled seizures.

         20. History of interstitial lung disease, idiopathic pulmonary fibrosis, pneumonitis
             (including drug induced), or evidence of active pneumonitis on screening chest CT
             scan.

         21. Major surgical procedure within 28 days prior to Cycle 1, Day 1 or anticipation of
             need for a major surgical procedure during the course of the study.

         22. Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy,
             endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal
             antibodies, or other investigational agent) 30 days prior to the first dose of study
             drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nasser K Altorki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cathy F Spinelli, RN, BSN</last_name>
    <phone>212-746-3328</phone>
    <email>caf2007@med.cornell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Spinelli, RN BSN</last_name>
      <phone>212-746-3328</phone>
      <email>caf2007@med.cornell.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 15, 2016</lastchanged_date>
  <firstreceived_date>May 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung neoplasms</keyword>
  <keyword>Bronchial Neoplasms</keyword>
  <keyword>Carcinoma, bronchogenic</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasms by site</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Respiratory Tract Neoplasms</keyword>
  <keyword>Thoracic Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified subject data for the primary and secondary outcomes will be made available after study completion.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
